UA125531C2 - ПІДШКІРНЕ ВВЕДЕННЯ АНТАГОНІСТА P2Y<sub>12</sub> РЕЦЕПТОРА - Google Patents
ПІДШКІРНЕ ВВЕДЕННЯ АНТАГОНІСТА P2Y<sub>12</sub> РЕЦЕПТОРА Download PDFInfo
- Publication number
- UA125531C2 UA125531C2 UAA201910293A UAA201910293A UA125531C2 UA 125531 C2 UA125531 C2 UA 125531C2 UA A201910293 A UAA201910293 A UA A201910293A UA A201910293 A UAA201910293 A UA A201910293A UA 125531 C2 UA125531 C2 UA 125531C2
- Authority
- UA
- Ukraine
- Prior art keywords
- administered
- administration
- pharmaceutically acceptable
- patient
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2017056175 | 2017-03-15 | ||
| PCT/EP2018/056372 WO2018167139A1 (en) | 2017-03-15 | 2018-03-14 | Subcutaneous administration of a p2y12 receptor antagonist |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA125531C2 true UA125531C2 (uk) | 2022-04-13 |
Family
ID=61899166
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA201910293A UA125531C2 (uk) | 2017-03-15 | 2018-03-14 | ПІДШКІРНЕ ВВЕДЕННЯ АНТАГОНІСТА P2Y<sub>12</sub> РЕЦЕПТОРА |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US11179390B2 (https=) |
| EP (1) | EP3595666A1 (https=) |
| JP (3) | JP7580918B2 (https=) |
| KR (1) | KR102510832B1 (https=) |
| CN (1) | CN110381947A (https=) |
| AU (1) | AU2018234056B2 (https=) |
| BR (1) | BR112019014567A2 (https=) |
| CL (1) | CL2019002318A1 (https=) |
| EA (1) | EA201992123A1 (https=) |
| IL (1) | IL269286B2 (https=) |
| MA (1) | MA49887A (https=) |
| MX (1) | MX393334B (https=) |
| MY (1) | MY205605A (https=) |
| PH (1) | PH12019502111A1 (https=) |
| SG (1) | SG11201908128YA (https=) |
| TW (1) | TWI765002B (https=) |
| UA (1) | UA125531C2 (https=) |
| WO (1) | WO2018167139A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3515924B1 (en) | 2016-09-22 | 2021-12-15 | Idorsia Pharmaceuticals Ltd | Crystalline forms |
| MA49887A (fr) * | 2017-03-15 | 2020-06-24 | Idorsia Pharmaceuticals Ltd | Administration sous-cutanée d'un antagoniste du récepteur p2y12 |
| SMT202600015T1 (it) | 2020-07-15 | 2026-03-09 | Viatris Asia Pacific Pte Ltd | Composizione farmaceutica acquosa comprendente un antagonista del recettore p2y12 |
| MX2024000653A (es) | 2021-07-13 | 2024-01-31 | Idorsia Pharmaceuticals Ltd | Un proceso para la sintesis de ester de butilo de acido 4-((r)-2-{[6-((s)-3-metoxi-pirrolidin-1-il)-2-fenil-pirimidin-4-c arbonil]-amino}-3-fosfono-propionil)-piperazin-1-carboxilico. |
| US20250197904A1 (en) | 2022-03-14 | 2025-06-19 | Viatris Asia Pacific Pte. Ltd. | A process for the synthesis of ( r)-2-(( tert-butoxycarbonyl)amino)-3-(diethoxyphosphoryl)propanoic acid or of phosphonate derivatives thereof |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3870035A (en) | 1970-07-17 | 1975-03-11 | Survival Technology | Method and apparatus for self-administering pre-hospital phase treatment of coronary prone individuals in the early minutes or hours after the onset of heart attack symptoms |
| US4004577A (en) | 1972-12-04 | 1977-01-25 | Survival Technology, Inc. | Method of treating heart attack patients prior to the establishment of qualified direct contact personal care |
| JPS5373586A (en) | 1976-12-09 | 1978-06-30 | Mitsubishi Chem Ind Ltd | New penicillin derivatives |
| US4795433A (en) | 1985-05-20 | 1989-01-03 | Survival Technology, Inc. | Automatic injector for emergency treatment |
| US4658830A (en) | 1984-08-08 | 1987-04-21 | Survival Technology, Inc. | Method and apparatus for initiating reperfusion treatment by an unattended individual undergoing heart attack symptoms |
| US5078680A (en) | 1984-08-08 | 1992-01-07 | Survival Technology, Inc. | Automatic injector for emergency treatment |
| GR861289B (en) | 1985-05-20 | 1986-09-16 | Survival Technology | Injection method and apparatus with electrical blood absorbing stimulation |
| CA2020437A1 (en) | 1989-07-05 | 1991-01-06 | Yoshihide Fuse | Cinnamamide derivative |
| JP2003502314A (ja) | 1999-06-14 | 2003-01-21 | イーライ・リリー・アンド・カンパニー | 化合物 |
| US6861424B2 (en) | 2001-06-06 | 2005-03-01 | Schering Aktiengesellschaft | Platelet adenosine diphosphate receptor antagonists |
| DE60333866D1 (de) | 2002-12-11 | 2010-09-30 | Bayer Schering Pharma Ag | 2-aminocarbonlyl-chinolin-verbindungen als adenosin diphosphat plättchenrezeptor antagonisten |
| ATE481103T1 (de) | 2003-04-09 | 2010-10-15 | Wyeth Llc | Derivate von 2-(8,9-dioxo-2,6- diazabicyclo(5.2.0)non-1(7)-en-2- yl)alkylphosphonsäure und deren verwendung als n- methyl-d-aspartat- (nmda-) rezeptorantagonisten |
| AU2003249865A1 (en) * | 2003-06-24 | 2005-01-21 | Actelion Pharmaceuticals Ltd | Pyrazolidinedione derivatives and their use as platelet aggregation inhibitors |
| TW200640877A (en) | 2005-04-28 | 2006-12-01 | Actelion Pharmaceuticals Ltd | Pyrimidine derivatives |
| AU2006305538B2 (en) | 2005-10-21 | 2012-06-28 | Idorsia Pharmaceuticals Ltd | Piperazine derivatives as antimalarial agents |
| CL2007002920A1 (es) | 2006-10-13 | 2008-06-06 | Actelion Pharmaceuticals Ltd | Compuestos derivados de 2-aminocarbonilpiridina; composicion farmaceutica; y uso para el tratamiento de trastornos vasculares oclusivos. |
| CL2007003038A1 (es) | 2006-10-25 | 2008-06-06 | Actelion Pharmaceuticals Ltd | Compuestos derivados de 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y uso en el tratamiento de trastornos vasculares oclusivos. |
| JP4785881B2 (ja) | 2007-02-27 | 2011-10-05 | 大塚製薬株式会社 | 医薬 |
| MX2009011089A (es) | 2007-04-23 | 2009-10-30 | Sanofi Aventis | Derivados de quinolina-carboxamida en calidad de antagonistas de p2y12. |
| CA2686203A1 (en) | 2007-05-02 | 2008-11-13 | Portola Pharmaceuticals, Inc. | Intravenous and oral dosing of a direct-acting and reversible p2y12 inhibitor |
| EP2225253B1 (en) | 2007-11-29 | 2012-06-27 | Actelion Pharmaceuticals Ltd. | Phosphonic acid derivates and their use as p2y12 receptor antagonists |
| EP2238127B1 (en) | 2007-12-26 | 2012-08-15 | Sanofi | Pyrazole-carboxamide derivatives as p2y12 antagonists |
| EP2238128B1 (en) | 2007-12-26 | 2012-08-22 | Sanofi | Heterocyclic pyrazole-carboxamides as p2y12 antagonists |
| AR071652A1 (es) | 2008-04-11 | 2010-07-07 | Actelion Pharmaceuticals Ltd | Derivados 2- fenil-piridina substituidos |
| AR071653A1 (es) | 2008-04-11 | 2010-07-07 | Actelion Pharmaceuticals Ltd | Derivados 2-fenil-4-ciclopropil-pirimidina |
| MA33260B1 (fr) | 2009-04-08 | 2012-05-02 | Actelion Pharmaceuticals Ltd | 6-(3-azabicyclo[3.1.0.]hex-3-yl)-2-phenylpyrimidines |
| CA2756654C (en) | 2009-04-22 | 2017-08-22 | Actelion Pharmaceuticals Ltd | Thiazole derivatives and their use as p2y12 receptor antagonists |
| WO2011137459A1 (en) * | 2010-04-30 | 2011-11-03 | Portola Pharmaceuticals, Inc. | Dosage forms of elinogrel and methods of injectable administration thereof |
| WO2011160768A1 (en) | 2010-06-23 | 2011-12-29 | Stefan Kralev | Medical device for self-administration of patients with acute coronary events |
| EP3515924B1 (en) | 2016-09-22 | 2021-12-15 | Idorsia Pharmaceuticals Ltd | Crystalline forms |
| MA49887A (fr) * | 2017-03-15 | 2020-06-24 | Idorsia Pharmaceuticals Ltd | Administration sous-cutanée d'un antagoniste du récepteur p2y12 |
-
2018
- 2018-03-14 MA MA049887A patent/MA49887A/fr unknown
- 2018-03-14 UA UAA201910293A patent/UA125531C2/uk unknown
- 2018-03-14 EA EA201992123A patent/EA201992123A1/ru unknown
- 2018-03-14 AU AU2018234056A patent/AU2018234056B2/en active Active
- 2018-03-14 CN CN201880017104.XA patent/CN110381947A/zh active Pending
- 2018-03-14 EP EP18715499.2A patent/EP3595666A1/en active Pending
- 2018-03-14 BR BR112019014567-2A patent/BR112019014567A2/pt not_active Application Discontinuation
- 2018-03-14 KR KR1020197029753A patent/KR102510832B1/ko active Active
- 2018-03-14 WO PCT/EP2018/056372 patent/WO2018167139A1/en not_active Ceased
- 2018-03-14 TW TW107108546A patent/TWI765002B/zh active
- 2018-03-14 US US16/494,254 patent/US11179390B2/en active Active
- 2018-03-14 JP JP2019549420A patent/JP7580918B2/ja active Active
- 2018-03-14 MY MYPI2019005278A patent/MY205605A/en unknown
- 2018-03-14 SG SG11201908128Y patent/SG11201908128YA/en unknown
- 2018-03-14 MX MX2019009559A patent/MX393334B/es unknown
-
2019
- 2019-08-16 CL CL2019002318A patent/CL2019002318A1/es unknown
- 2019-09-11 IL IL269286A patent/IL269286B2/en unknown
- 2019-09-13 PH PH12019502111A patent/PH12019502111A1/en unknown
-
2023
- 2023-01-23 JP JP2023008155A patent/JP2023052576A/ja active Pending
-
2024
- 2024-12-26 JP JP2024230902A patent/JP2025060907A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2018234056A1 (en) | 2019-10-31 |
| TW201840323A (zh) | 2018-11-16 |
| SG11201908128YA (en) | 2019-10-30 |
| EP3595666A1 (en) | 2020-01-22 |
| EA201992123A1 (ru) | 2020-02-25 |
| IL269286B1 (en) | 2023-04-01 |
| JP2020510043A (ja) | 2020-04-02 |
| BR112019014567A2 (pt) | 2020-02-18 |
| US11179390B2 (en) | 2021-11-23 |
| TWI765002B (zh) | 2022-05-21 |
| PH12019502111A1 (en) | 2020-03-16 |
| CN110381947A (zh) | 2019-10-25 |
| WO2018167139A1 (en) | 2018-09-20 |
| IL269286B2 (en) | 2023-08-01 |
| KR102510832B1 (ko) | 2023-03-15 |
| US20200129510A1 (en) | 2020-04-30 |
| IL269286A (en) | 2019-11-28 |
| MA49887A (fr) | 2020-06-24 |
| KR20190124297A (ko) | 2019-11-04 |
| CL2019002318A1 (es) | 2020-01-10 |
| JP2023052576A (ja) | 2023-04-11 |
| AU2018234056B2 (en) | 2023-05-25 |
| MY205605A (en) | 2024-10-29 |
| MX393334B (es) | 2025-03-24 |
| JP7580918B2 (ja) | 2024-11-12 |
| JP2025060907A (ja) | 2025-04-10 |
| CA3050831A1 (en) | 2018-09-20 |
| NZ757938A (en) | 2024-07-05 |
| MX2019009559A (es) | 2019-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA125531C2 (uk) | ПІДШКІРНЕ ВВЕДЕННЯ АНТАГОНІСТА P2Y<sub>12</sub> РЕЦЕПТОРА | |
| CN119424616B (zh) | Gip/glp1激动剂组合物 | |
| JP2022116191A (ja) | 異常な新生血管形成を伴う眼疾患を処置するためにニンテダニブを使用する組成物および方法 | |
| TWI881480B (zh) | 克立咪唑(clemizole)化合物於預防及治療肝癌之用途 | |
| KR101996245B1 (ko) | 선택적 s1p1 수용체 아고니스트를 포함하는 약학 조합물 | |
| US8691844B2 (en) | Method for treating thrombosis and inhibiting platelet aggregation with 21-(S)-argatroban | |
| KR20060130195A (ko) | 알칼로이드 제형 | |
| TW201737943A (zh) | 使用fasn抑制劑之方法 | |
| NZ580868A (en) | Dosages and methods for the treatment of cancer | |
| US20250243218A1 (en) | Novel carbamate compound and use thereof | |
| JP7850665B2 (ja) | 血管脂肪腫の処置のための組成物 | |
| KR20170095926A (ko) | 설폰아마이드류 약학 조성물 | |
| JP6950966B2 (ja) | スガマデクス又はその薬理学的に許容される塩含有液剤及びその製造方法 | |
| JP7618235B2 (ja) | ｐ－ボロノフェニルアラニンを含有する注射液剤の析出防止方法 | |
| CA3050831C (en) | Subcutaneous administration of a p2y12 receptor antagonist | |
| EP3782620B1 (en) | Pharmaceutical composition comprising 1,2-naphthoquinone derivative for use in preventing or treating acute myeloid or lymphoblastic leukemia | |
| CN111388418B (zh) | 一种含有罗哌卡因或其药用盐的药物组合物 | |
| EA042138B1 (ru) | Подкожное введение антагониста p2y12 рецептора | |
| RU2860343C2 (ru) | Водный фармацевтический состав на основе гидрокортизона натрия фосфата и монотиоглицерина | |
| JPH09104627A (ja) | アパファントを主薬とする水性点眼剤 | |
| EP4714445A1 (en) | Novel composition for preventing or treating retinal diseases | |
| JPS5857431B2 (ja) | 脳血管拡張剤２，３−置換−４−複素環状アミノスルホニルベンゼンスルホンアミドの製法 | |
| JP3571114B2 (ja) | 麻薬拮抗剤 | |
| NZ762767B2 (en) | Aripiprazole formulations having increased injection speeds |